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As they expand, solid tumors can rapidly
outgrow the carrying capacity of the local
vasculature; this phenomenon is typical-
ly aggravated by the chaotic vascular
structures that form during malignant
growth. Thus, tumors are often riddled
with areas of lowered oxygen content, or
hypoxia, which has many
therapeutic ramifications.
First, hypoxic regions of
tumors are much more
resistant to radiation, an
important problem in radio-
therapy. Second, hypoxia
induces release of angio-
genic factors such as
VEGF (vascular endothe-
lial growth factor), and thus
contributes to tumor vascu-
larization. Finally, chronic
hypoxia within tumors can
select for cells resistant to
hypoxia-induced apopto-
sis; these cells often have
mutations in the p53 gene;
therefore, hypoxia can indi-
rectly contribute to the
process of malignant pro-
gression at the genetic
level (Graeber et al., 1996).
When exposed to low-
ered levels of oxygen, tis-
sues compensate in a vari-
ety of ways, ranging from
the systemic adjustments
caused by increased ery-
thropoietin production to 
the tissue-specific effects 
of increased VEGF ex-
pression and the largely
cell-autonomous effects of
increased glycolysis (re-
viewed in Semenza, 1999).
All of these adaptations 
to hypoxia are regulated
wholly or in part by the
hypoxia-inducible transcrip-
tion factor (HIF) complex.
The oxygen-regulated com-
ponents of this complex are
the HIFα subunits. To date,
three members of the HIFα
family have been cloned:
HIF-1α, HIF-2α, and HIF-
3α. Of the HIFα subunits,
the function of HIF-1α has
been the most extensively characterized.
Of note as well, thus far, there appears to
be little redundancy between HIF-1α and
HIF-2α function based on phenotypes of
mice lacking either gene.
During normoxia, the HIFα subunits
are rapidly degraded, directed by their
interaction with the von Hippel-Lindau
(VHL) tumor suppressor protein, in a
complex that induces ubiquitination and
eventual destruction of the subunit by the
proteasome (reviewed in Kondo and
Kaelin, 2001). In familial disease, het-
erozygosity for the von Hippel-Lindau
mutations (VHL) gives rise to a
wide range of solid tumors,
including clear cell renal carci-
nomas, the most common sub-
type of renal cell carcinomas
(RCC). Spontaneous deletion of
VHL is also a common cause of
sporadic renal clear-cell carci-
noma; mutations in VHL are
found in 50%–80% of these
tumors. In the United States,
almost 30,000 patients are diag-
nosed with RCC each year;
these tumors tend to be highly
vascularized; when metastatic,
the median survival is less than
one year (Karumanchi et al.,
2002).
To date, the only proteins
that are clearly substrates of the
VHL complex are HIF-1α and
HIF-2α. In response to hypoxia,
HIF-α proteins are stabilized;
therefore, loss of VHL expres-
sion represents a potent mecha-
nism to achieve overexpression
of the HIFα subunits. In fact,
previous studies in cell lines and
in vivo have suggested that
most, if not all, phenotypic
effects of the loss of VHL may
be due to the normoxic stabiliza-
tion of HIF and increased
expression of HIF dependent
genes such as VEGF (Wiesener
et al., 2001).
A key question with regards
to the biology of the hypoxic
response has been whether 
HIF is a positive or negative reg-
ulator of tumor growth. In con-
trast to most normal tissues,
which lack detectable HIFα
staining, expression of HIF-1α
has been reported in a variety 
of human tumors, including
prostate, breast, and colon can-
cers (Zhong et al., 1999). The
staining was noted especially in
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HIF-2α overexpression directly contributes to renal clear cell tumorigenesis: evidence for HIF as a tumor promoter.
Figure 1. The pathway from VHL to renal cell carcinoma
The steps from loss of VHL to tumorigenesis are becoming more
defined. Solid arrows and lines represent the correlations between
known genetic pathways and corresponding specific genes that are
affected by loss of VHL; dotted arrows and lines represent relationships
that have been described, but remain uncertain. In summary, loss of
VHL permits constitutive expression of HIF-1α and HIF-2α, and possibly
other yet to be identified targets of proteasomal degradation. In this
issue of Cancer Cell, Kondo et al. (2002) and Maranchie et al. (2002)
have described the importance of HIF-2α with respect to growth of
renal cell carcinoma; however, it remains unknown whether other HIFα
subunits contribute to RCC via redundant or overlapping functions.
Overexpression of HIFα subunits results in the induction of several clas-
sical HIF-1 target genes, even in the absence of hypoxia, such as Glut-
1, VEGF, and PGK. These target genes are in turn responsible for stimu-
lating the angiogenic and metabolic changes that manifest as
increased tumor microvessel density and acidosis, hallmarks of a vari-
ety of tumor types. The role that hypoxia plays with respect to cell
cycle progression/arrest and/or apoptosis is less well-defined.
Nevertheless, it is likely that dysregulation at any point in the hierarchy
contributes to the development of renal cell carcinoma, as well as
other malignancies observed in patients with VHL mutations.
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areas of necrosis or on the borders of
necrotic cells, presumably the cells
exposed to the most severe hypoxia. In
contrast, in RCC, HIF-1α staining is
detected throughout the tumor, presum-
ably due to constitutive overexpression
(Karumanchi et al., 2002).
In mouse xenograft models, striking
differences in growth rates of tumors
have been reported using genetically
modified cell lines that lack HIF-1 activity.
In three studies, HIF-1α has been identi-
fied as a positive regulator of tumor
growth (Maxwell et al., 1997; Ryan et al.,
1998, 2000). A variety of HIF-1 null cell
types were used in these studies, includ-
ing embryonic stem (ES) cells lacking
HIF-1α, transformed fibroblasts lacking
HIF-1α, and hepatoma cells lacking HIF-
1β. In contrast to these results, other
investigators have reported that tumors
derived from ES cells lacking HIF-1α can
grow faster than wild-type tumors as a
result of decreased rates of apoptosis
(Carmeliet et al., 1998). The reasons for
these discrepancies remain unclear,
although clonal effects are likely to be
the source of some of the differences
seen.
Another key question is whether
HIFα subunits are necessary/sufficient
to induce increased microvessel density
(MVD) observed in a majority of human
tumors. Again, there is controversy
regarding the role of HIF-1α in tumor
angiogenesis, since depending on the
cell type utilized to derive HIF-1α tumors,
the tumors either exhibit decreased or
equivalent MVD. For example, a recent
study of 60 human ovarian tumors did
not find a significant relationship
between MVD and HIF-1α expression,
nor a correlation between MVD and HIF-
1α expression in survival (Nakayama et
al., 2002).
The recent work by Maranchie et al.
(2002) and Kondo et al. (2002), present-
ed in this issue of Cancer Cell, is the first
attempt to directly test and compare the
individual contribution of HIFα subunits
to tumorigenesis. Their results support
the growing consensus that the HIFα
proteins function to promote tumor
growth of a variety of tumor types.
Both Maranchie and Kondo have uti-
lized an RCC line derived from a spo-
radic renal clear cell carcinoma (786-0),
in which one allele of VHL has been lost,
and the other inactivated by a truncation
at amino acid 104.This cell line has been
previously reported to overexpress HIF-
2α, as well as HIF target genes such as
VEGF and glucose-transporter-1 (Glut-
1). These cells lack detectable expres-
sion of HIF-1α protein. Both groups uti-
lized RCC lines previously created by
Illiopoulos et al. (1995), in which either
VHL or empty vector were stably trans-
fected into parental 786-0 cells in order
to create VHL wild-type or null RCC
lines. Although both groups use mouse
xenograft models of their modified RCC
lines to arrive at similar conclusions, they
approach the question of the role of the
HIFα subunits in renal cell tumorigenesis
in differing ways, by independently inves-
tigating the effects of overexpression of
either HIF-1α and HIF-2α (the latter indi-
rectly) (Maranchie et al., 2002) or HIF-2α
(Kondo et al., 2002) independently of
VHL status.
In light of recent observations that
proline hydroxylase activity is required
for interaction with VHL and subsequent
degradation of the HIFα subunits, both
groups mutated key proline residues of
either HIF-1α or HIF-2α to allow constitu-
tive expression. Kondo et al. (2002) com-
pare the growth of tumors in VHL wild-
type cells to cells that express both wild-
type VHL as well as a point mutant of
HIF-2α (P531A). Similarly, Maranchie et
al. (2002)  have mutated P564 of HIF-1α
and compared tumor growth to VHL wild-
type or null cells. In addition, Maranchie
et al. (2002) have created cells that
express a blocking peptide derived from
the VHL binding domain of HIF-1α (the
oxygen-dependent domain, ODD) that
functions to prevent association of either
HIFα with pVHL, allowing constitutive
overexpression of HIF-2α (since these
cells lack HIF-1α expression).
In this issue of Cancer Cell, Kondo et
al. (2002) demonstrate that introduction
of the HIF2αP531A mutant into 786-0
cells wild-type for VHL accelerated tumor
growth rate, and increased tumor net
weight approximately 50%. Results
obtained by Maranchie et al. (2002) indi-
cate that tumor size is approximately
equivalent between RCC cells lacking
VHL and RCC cells that are wild-type for
VHL, but express the ODD blocking pep-
tide; this confirms that overexpression of
HIFα subunits promotes tumorigenesis
in these cells. Interestingly, overexpres-
sion of HIF-1α in a VHL-independent
fashion impaired tumor growth; this,
together with the blocking peptide data
and the data from Kondo et al. (2002),
would argue that the tumor-promoting
HIFα is in fact HIF-2α in these cell lines.
Although both groups demonstrate
that dysregulation of HIF-2α promotes
tumorigenesis in RCC, it is interesting to
note that there are some histological dif-
ferences seen in the two papers. Of par-
ticular note, the clear cell phenotype is
observed in tumors overexpressing HIF-
2α (Kondo et al., 2002), but not in the
blocking peptide expressing mutants
(described in Maranchie et al., 2002),
which are also characterized by high lev-
els of HIF-2α expression. Indeed, such
discrepancies are common in cell culture
models following sequential manipula-
tion and passaging, and will need to be
resolved to determine the exact role of
HIF-2α with respect to the clear cell mor-
phology.
In summary, these novel investiga-
tions of HIFα function have suggested
that overexpression of HIF-2α (and, in
the case of Maranchie et al. [2002], not
HIF-1α) promotes tumor cell growth in
an RCC-derived cell line.These observa-
tions, in turn, have exciting implications
for the specification of the role(s) of HIF-
1α and HIF-2α in promoting tumor
growth. A model that summarizes the
genetic alterations proposed to result in
RCC is presented in Figure 1. In addi-
tion, there are intriguing suggestions that
HIF-1α and HIF-2α differ substantially in
their functions during tumorigenesis.
Follow-up studies that characterize the
specific genetic pathways controlled by
these two different hypoxia-responsive
transcription factors should provide
exciting insights into how hypoxia
shapes and controls the growth of solid
tumors.
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On a worldwide basis, gastric cancer is a
major cancer-related killer. In Japan and
certain other Asian countries gastric can-
cer tops the list of cancer-induced deaths.
While clear links have been discovered
between environmental factors, such as
Helicobacter pylori infection, dietary com-
ponents, and gastric cancer frequencies,
the genetic basis for gastric cancer devel-
opment is still largely unclear. In the April
5 issue of Cell, Li and coworkers (2002)
describe the uncovering of RUNX3/
AML2/CBFA3/PEBP2αC as a candidate
tumor suppressor in gastric cancer devel-
opment. RUNX3 belongs to the Runt
domain family of transcription factors,
which consists of 3 DNA binding α sub-
units, RUNX1, RUNX2, and RUNX3 (see
Table 1 for alternative names), each of
which is capable of forming heterodimers
with the common β subunit CBFβ. RUNX
heterodimers are relatively weakly acting
transcriptional regulators, the potency of
which can be induced by associations
with transcriptional (co)activators, such
as MYB, ETS, and p300/CBP, or co-
repressors such as TLE1 and mSin3A
(Perry et al., 2002). The main family fea-
ture, the 128 amino acid runt domain
named for its high homology to the
Drosophila pair-rule protein runt, facili-
tates dimerization and DNA binding. Like
their counterparts in D. melanogaster
and C. elegans, mammalian RUNX fami-
ly transcription factors play important
roles in cell fate determination during
development.
The work of Li and coworkers
(2002) completes the mouse knockout
analyses of the Runx family and under-
scores the role of Runt family members
as cancer-related genes. As previously
found for Runx1 (Okuda et al., 1996),
Runx2 (Otto et al., 1997), and Cfbβ
(Wang et al., 1996), genetic ablation of
Runx3 has profound effects. While
Runx3 knockout mice are born in
Mendelian ratios, they die soon after
birth probably due to starvation. Runx3
is strongly expressed in gastrointestinal
organs in the developing embryo and
throughout adult life of the mouse and
the gastric epithelium in Runx3 knock-
outs displays hyperplasia and a reduced
apoptotic rate. Interestingly, when ana-
lyzed in primary cultures Runx3−/− gastric
epithelial cells are less sensitive to TGF-
β-mediated growth inhibition, based on a
marked failure to enter apoptosis when
treated with TGF-β. To investigate the
potential connection between RUNX3
and gastric cancers in humans, Li et al.
(2002) analyze a series of gastric cancer
cell lines and primary human gastric
tumors. Out of 46 primary human
tumors, 30% displayed hemizygosity of
RUNX3 with a significant correlation
between RUNX3 loss and gastric cancer
progression stage. Furthermore, RUNX3
expression analysis revealed that on
average 60% of the analyzed primary
human gastric tumors exhibited reduced
RUNX3 levels rising to nearly 90%
among the late stage, representing high-
ly metastatic tumors. Upon examination
of 119 tumor samples, Li et al. were able
to identify only a single nucleotide transi-
tion causing an arginine-to-cytosine con-
version within the conserved Runt
domain, which did not strengthen the
tumor suppressor argument much.
However, the high CpG nucleotide con-
tent triggered analysis of DNA methyla-
tion status, and interestingly RUNX3
hypermethylation in a large number of
primary tumor samples was found to cor-
relate with gene silencing, which indi-
cates an unusual strong prevalence for
epigenetic gene silencing. To further
establish a causal link between RUNX3
expression and oncogenesis, Li et al.
injected gastric cancer cells engineered
to overexpress either wild-type or Runt
domain mutated RUNX3 into nude mice.
While RUNX3 mediated a significant
reduction in tumorigenicity, the Runt
domain mutant aggravated tumor forma-
tion. Moreover, gastric epithelial cells
immortalized by loss of p53 only were
able to form tumors in nude mice when
Runx3 was also deleted. Together, these
results underline the role of RUNX3 as a
bona fide tumor suppressor.
It is now clear that all three Runx
family members play important roles in
normal developmental processes as
well as in cancers (Table 1). RUNX1,
perhaps better known as AML1, plays a
critical role in hematopoietic develop-
ment, and genetic ablation of either
Runx1 or Cbfβ results in embryonic
RUNX: A trilogy of cancer genes
The RUNX family of transcription factors plays pivotal roles during normal development and in neoplasias. Recent data
involve RUNX3 as an important tumor suppressor in gastric cancers and pose interesting questions about how perturbed
levels and interspecific competition among RUNX family members may contribute to tumorigenesis.
